The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical CMO and CDMO Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 API CMO and CDMO
1.2.3 FDF CMO and CDMO
1.2.4 Packaging CMO
1.2.5 Clinical CDMO
1.3 Market by Application
1.3.1 Global Pharmaceutical CMO and CDMO Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical CMO and CDMO Market Perspective (2018-2029)
2.2 Pharmaceutical CMO and CDMO Growth Trends by Region
2.2.1 Global Pharmaceutical CMO and CDMO Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pharmaceutical CMO and CDMO Historic Market Size by Region (2018-2023)
2.2.3 Pharmaceutical CMO and CDMO Forecasted Market Size by Region (2024-2029)
2.3 Pharmaceutical CMO and CDMO Market Dynamics
2.3.1 Pharmaceutical CMO and CDMO Industry Trends
2.3.2 Pharmaceutical CMO and CDMO Market Drivers
2.3.3 Pharmaceutical CMO and CDMO Market Challenges
2.3.4 Pharmaceutical CMO and CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical CMO and CDMO Players by Revenue
3.1.1 Global Top Pharmaceutical CMO and CDMO Players by Revenue (2018-2023)
3.1.2 Global Pharmaceutical CMO and CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Pharmaceutical CMO and CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmaceutical CMO and CDMO Revenue
3.4 Global Pharmaceutical CMO and CDMO Market Concentration Ratio
3.4.1 Global Pharmaceutical CMO and CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CMO and CDMO Revenue in 2022
3.5 Pharmaceutical CMO and CDMO Key Players Head office and Area Served
3.6 Key Players Pharmaceutical CMO and CDMO Product Solution and Service
3.7 Date of Enter into Pharmaceutical CMO and CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical CMO and CDMO Breakdown Data by Type
4.1 Global Pharmaceutical CMO and CDMO Historic Market Size by Type (2018-2023)
4.2 Global Pharmaceutical CMO and CDMO Forecasted Market Size by Type (2024-2029)
5 Pharmaceutical CMO and CDMO Breakdown Data by Application
5.1 Global Pharmaceutical CMO and CDMO Historic Market Size by Application (2018-2023)
5.2 Global Pharmaceutical CMO and CDMO Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Pharmaceutical CMO and CDMO Market Size (2018-2029)
6.2 North America Pharmaceutical CMO and CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pharmaceutical CMO and CDMO Market Size by Country (2018-2023)
6.4 North America Pharmaceutical CMO and CDMO Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical CMO and CDMO Market Size (2018-2029)
7.2 Europe Pharmaceutical CMO and CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pharmaceutical CMO and CDMO Market Size by Country (2018-2023)
7.4 Europe Pharmaceutical CMO and CDMO Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical CMO and CDMO Market Size (2018-2029)
8.2 Asia-Pacific Pharmaceutical CMO and CDMO Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pharmaceutical CMO and CDMO Market Size by Region (2018-2023)
8.4 Asia-Pacific Pharmaceutical CMO and CDMO Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical CMO and CDMO Market Size (2018-2029)
9.2 Latin America Pharmaceutical CMO and CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pharmaceutical CMO and CDMO Market Size by Country (2018-2023)
9.4 Latin America Pharmaceutical CMO and CDMO Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical CMO and CDMO Market Size (2018-2029)
10.2 Middle East & Africa Pharmaceutical CMO and CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pharmaceutical CMO and CDMO Market Size by Country (2018-2023)
10.4 Middle East & Africa Pharmaceutical CMO and CDMO Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Detail
11.1.2 Lonza Business Overview
11.1.3 Lonza Pharmaceutical CMO and CDMO Introduction
11.1.4 Lonza Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Detail
11.2.2 Catalent Business Overview
11.2.3 Catalent Pharmaceutical CMO and CDMO Introduction
11.2.4 Catalent Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.2.5 Catalent Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Detail
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Pharmaceutical CMO and CDMO Introduction
11.3.4 Thermo Fisher Scientific Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Detail
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Pharmaceutical CMO and CDMO Introduction
11.4.4 Samsung Biologics Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.4.5 Samsung Biologics Recent Development
11.5 Fareva
11.5.1 Fareva Company Detail
11.5.2 Fareva Business Overview
11.5.3 Fareva Pharmaceutical CMO and CDMO Introduction
11.5.4 Fareva Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.5.5 Fareva Recent Development
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Detail
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Pharmaceutical CMO and CDMO Introduction
11.6.4 WuXi AppTech Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.6.5 WuXi AppTech Recent Development
11.7 WuXi Biologics
11.7.1 WuXi Biologics Company Detail
11.7.2 WuXi Biologics Business Overview
11.7.3 WuXi Biologics Pharmaceutical CMO and CDMO Introduction
11.7.4 WuXi Biologics Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.7.5 WuXi Biologics Recent Development
11.8 Siegfried
11.8.1 Siegfried Company Detail
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Pharmaceutical CMO and CDMO Introduction
11.8.4 Siegfried Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.8.5 Siegfried Recent Development
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Detail
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CMO and CDMO Introduction
11.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.10 Asymchem
11.10.1 Asymchem Company Detail
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Pharmaceutical CMO and CDMO Introduction
11.10.4 Asymchem Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.10.5 Asymchem Recent Development
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Company Detail
11.11.2 Pfizer CentreOne Business Overview
11.11.3 Pfizer CentreOne Pharmaceutical CMO and CDMO Introduction
11.11.4 Pfizer CentreOne Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.11.5 Pfizer CentreOne Recent Development
11.12 Delpharm
11.12.1 Delpharm Company Detail
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Pharmaceutical CMO and CDMO Introduction
11.12.4 Delpharm Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.12.5 Delpharm Recent Development
11.13 Recipharm
11.13.1 Recipharm Company Detail
11.13.2 Recipharm Business Overview
11.13.3 Recipharm Pharmaceutical CMO and CDMO Introduction
11.13.4 Recipharm Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.13.5 Recipharm Recent Development
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Company Detail
11.14.2 AGC Pharma Chemicals Business Overview
11.14.3 AGC Pharma Chemicals Pharmaceutical CMO and CDMO Introduction
11.14.4 AGC Pharma Chemicals Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.14.5 AGC Pharma Chemicals Recent Development
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Company Detail
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Pharmaceutical CMO and CDMO Introduction
11.15.4 Boehringer Ingelheim Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.15.5 Boehringer Ingelheim Recent Development
11.16 Vetter
11.16.1 Vetter Company Detail
11.16.2 Vetter Business Overview
11.16.3 Vetter Pharmaceutical CMO and CDMO Introduction
11.16.4 Vetter Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.16.5 Vetter Recent Development
11.17 Curia
11.17.1 Curia Company Detail
11.17.2 Curia Business Overview
11.17.3 Curia Pharmaceutical CMO and CDMO Introduction
11.17.4 Curia Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.17.5 Curia Recent Development
11.18 Aenova
11.18.1 Aenova Company Detail
11.18.2 Aenova Business Overview
11.18.3 Aenova Pharmaceutical CMO and CDMO Introduction
11.18.4 Aenova Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.18.5 Aenova Recent Development
11.19 Porton
11.19.1 Porton Company Detail
11.19.2 Porton Business Overview
11.19.3 Porton Pharmaceutical CMO and CDMO Introduction
11.19.4 Porton Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.19.5 Porton Recent Development
11.20 Piramal
11.20.1 Piramal Company Detail
11.20.2 Piramal Business Overview
11.20.3 Piramal Pharmaceutical CMO and CDMO Introduction
11.20.4 Piramal Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.20.5 Piramal Recent Development
11.21 Strides Pharma
11.21.1 Strides Pharma Company Detail
11.21.2 Strides Pharma Business Overview
11.21.3 Strides Pharma Pharmaceutical CMO and CDMO Introduction
11.21.4 Strides Pharma Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.21.5 Strides Pharma Recent Development
11.22 NextPharma
11.22.1 NextPharma Company Detail
11.22.2 NextPharma Business Overview
11.22.3 NextPharma Pharmaceutical CMO and CDMO Introduction
11.22.4 NextPharma Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.22.5 NextPharma Recent Development
11.23 Famar
11.23.1 Famar Company Detail
11.23.2 Famar Business Overview
11.23.3 Famar Pharmaceutical CMO and CDMO Introduction
11.23.4 Famar Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.23.5 Famar Recent Development
11.24 Jubilant
11.24.1 Jubilant Company Detail
11.24.2 Jubilant Business Overview
11.24.3 Jubilant Pharmaceutical CMO and CDMO Introduction
11.24.4 Jubilant Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.24.5 Jubilant Recent Development
11.25 Alcami
11.25.1 Alcami Company Detail
11.25.2 Alcami Business Overview
11.25.3 Alcami Pharmaceutical CMO and CDMO Introduction
11.25.4 Alcami Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.25.5 Alcami Recent Development
11.26 Euroapi
11.26.1 Euroapi Company Detail
11.26.2 Euroapi Business Overview
11.26.3 Euroapi Pharmaceutical CMO and CDMO Introduction
11.26.4 Euroapi Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.26.5 Euroapi Recent Development
11.27 Eurofins
11.27.1 Eurofins Company Detail
11.27.2 Eurofins Business Overview
11.27.3 Eurofins Pharmaceutical CMO and CDMO Introduction
11.27.4 Eurofins Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.27.5 Eurofins Recent Development
11.28 Avid Bioservices
11.28.1 Avid Bioservices Company Detail
11.28.2 Avid Bioservices Business Overview
11.28.3 Avid Bioservices Pharmaceutical CMO and CDMO Introduction
11.28.4 Avid Bioservices Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.28.5 Avid Bioservices Recent Development
11.29 BioVectra
11.29.1 BioVectra Company Detail
11.29.2 BioVectra Business Overview
11.29.3 BioVectra Pharmaceutical CMO and CDMO Introduction
11.29.4 BioVectra Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.29.5 BioVectra Recent Development
11.30 CPL
11.30.1 CPL Company Detail
11.30.2 CPL Business Overview
11.30.3 CPL Pharmaceutical CMO and CDMO Introduction
11.30.4 CPL Revenue in Pharmaceutical CMO and CDMO Business (2018-2023)
11.30.5 CPL Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details